1665-60-7

Basic information

• Product Name: diethyl-(4-amino-phenethyl)-amine
• Synonyms: diethyl-(4-amino-phenethyl)-amine
• CAS NO: 1665-60-7
• Molecular Weight: 192.304
• Mol File: 1665-60-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: diethyl-(4-amino-phenethyl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl-(4-amino-phenethyl)-amine(1665-60-7)
• EPA Substance Registry System: diethyl-(4-amino-phenethyl)-amine(1665-60-7)

Safety Data

• Hazardous Substances Data: 1665-60-7(Hazardous Substances Data)

Upstream product

• 5300-21-0 N,N-diethylphenethylamine 
• 555-16-8 4-nitrobenzaldehdye 
• 5345-22-2 diethyl-(4-nitro-phenethyl)-amine 
• 50507-86-3 Diethylamide of p-nitrophenylacetic acid 
• 51738-10-4 2,2-dibromo-1-(4-nitrophenyl)ethene 
• 20264-95-3 2-(4-nitrophenyl)ethyl chloride 
• 109-89-7 diethylamine 
• 3544-25-0 p-aminophenylacetonitrile 

Downstream Products

• 38519-58-3 benzothiazol-2-yl-[4-(2-diethylamino-ethyl)-phenyl]-amine 

Relevant articles and documents

Synthesis and biological evaluation of new 4β-anilino-4′-O- demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

A series of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4β position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route.

Beta-ketoamide compounds with MCH antagonistic activity

Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to hydroxybenzimidazole pyrimidines or pyridines or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.